New York Investment Groups Recommends Listing INJEX Pharma AG on NASDAQ
The financial roadshow of INJEX Pharma AG, Germany, was an excellent success. Feedback from the American financial community for the needle free injection technology has been great.
(PRWEB) June 20, 2012
The management of INJEX Pharma AG, a health care company based in Berlin, Germany, visited New York for a financial road show in the first week of June and presented the innovative products, INJEX and ROJEX, needle free and painless injection systems to selected investment groups.
The CEO, Mr. Andy Rösch and the Director for international sales, Mr. Sylwin Grinman, are convinced that the technology, which was introduced more than ten years ago, has great worldwide market potential today. We offer our worldwide network of distributors exclusive signed agreements. The start of marketing and sales in the US market is just ahead. At the end of May the company received the FDA 510(k) registration for marketing and sales of the INJEX products in the United States of America. This is an important milestone especially for the New York financial community.
INJEX Pharma AG impressed by presenting the beauty kit SHIREEN with the new Poring – Method for a soft wrinkle treatment. This new method combined with the SHIREEN Fluid has -big market potential and shall acquire the market between the skin creams and the injection method with different products.
Sylwin Grinman, INJEX Pharma USA in Miami says; “We will offer more as we plan for the future. We have an innovative concept, we are going new ways, entering new markets and are seeking new market potentials. INJEX for the medical markets and SHIREEN for the cosmetic markets will yield market share with our new marketing and sales concept. “
New York investment bankers recommended after the presentation a listing on the NASDAQ and offered their services to accompany INJEX Pharma AG. The CEO and the supervisory board will check the opportunities for such a listing with selected investment bankers in New York.
According to Andy Rösch, “This was a ground - breaking experience for our us to have the chance to present the company, the history and the future potential in New York. American bankers are focusing on the future and we were able to present and convince in a reliable manner. We are diversifying and entering new markets like the profitable cosmetic market. The proposal for a NASDAQ listing definitely amazed us . We want to take this American challenge, because this would be a huge opportunity for the company and the shareholders. Now we have to evaluate whether the company has all the basics to go this step. “
Georgina Fahrer
Injex Pharma
305 778 1489
Email Information
http://news.yahoo.com/york-investment-groups-recommends-listing-injex-pharma-ag-080312340.html